Full-Time
Quality Lead
Quality Assurance, CDMO
Updated on 5/20/2026
Mytos
11-50 employees
Automated scalable human cell manufacturing platform
No salary listed
London, UK + 1 more
More locations: Letchworth Garden City, UK
In Person
 QA & Testing (1) |
|---|
- Significant QA experience (>5 years) in a GxP environment, ideally in Advanced Therapy Medicinal Products, biologics, or cell therapy
- Strong understanding of MHRA and EU Good Manufacturing Practice, with hands-on experience preparing for inspections
- Experience with Production Quality System covering document control, deviations, CAPA, change control, validation, and training
- You meet MHRA requirements to be a Quality Controller on the MIA(IMP) license
- Experience in auditing and being audited
- Comfortable working in a fast paced environment
- Excellent written and verbal communication skills
- Lead Mytos an MHRA MIA(IMP) license for our the first site as fast as possible, without compromising on quality
- Take the lead in establishing a robust and scalable Production Quality System, and maintaining it
- Ensure all aspects of our production are managed in compliance with our quality policies and procedures
- Elevate the team’s quality understanding, and reinforce an efficient quality culture
- Work with leadership to plan quality strategy to hit our business goals
- Lead and support audits
- Prepare Mytos for future commercial batch release
- Experience in the release of Advanced Therapy Medicinal Products products - PSC-derived Cell Therapies
- Have previously setup a Production Quality System from scratch, and obtained a MIA(IMP) license
- Experience setting up electronic systems such as electronic Quality Management System (MasterControl) and electronic Batch Records/Manufacturing execution systems
- Knowledge and experience with U.S. Food and Drug Administration regulations
Mytos.bio provides automated, end-to-end manufacturing for human cell types used in biotech. It sells and supports its proprietary Mytos Platform, which combines robotics and software to run cell culture processes without needing more staff. This turns traditional artisanal cell culture into scalable, repeatable production for large biotech firms working on cell therapies and drug development. The system works by integrating automated equipment and software workflows that manage culture, monitoring, and quality control, enabling consistent, high-quality cells at scale. Compared with competitors, Mytos.bio emphasizes a turnkey, scalable infrastructure that reduces headcount while delivering uniform results, backed by a team of hardware and software engineers and biologists, and recognition as a YCombinator alumnus and Forbes 30 Under 30. Its goal is to make large-scale cell production reliable and cost-effective so biopharma companies can accelerate therapies and drug development.
Company Size
11-50
Company Stage
Series A
Total Funding
$20.9M
Headquarters
London, United Kingdom
Founded
2016
Simplify's Take
What believers are saying
- $19M Series A from Buckley Ventures accelerates iDEM platform growth.
- Partnerships with StemSight, Rinri, Novadip scale cell therapies for trials.
- Aspen Neuroscience collaboration produces DANPCs for Parkinson's ANPD001.
What critics are saying
- Aspen ANPD001 trial failure terminates Mytos contract, cuts payments.
- Lonza Cocoon captures 40% market with GMP compliance over iDEM.
- UK AI Act audits iDEM software, delays deployments, raises costs 30%.
What makes Mytos unique
- Mytos' iDEM platform fully automates stem cell differentiation to specific human cell types.
- iDEM integrates fluidics, imaging, and robotics for hands-off, scalable cell production.
- Y Combinator alumnus Mytos targets biotech firms with precision cell manufacturing.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Mytos who can refer or advise you
Benefits
Stock Options
Pension
Lunch covered daily
24 days holiday (excluding bank holidays)
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 2%2 year growth
↑ 2%Mytos announces strategic partnerships with StemSight, Rinri Therapeutics, and Novadip to power next-generation cell therapy trials.
Mytos’ automated cell culture technology will power manufacturing of dopaminergic neuronal precursor cells for Aspen’s investigational cell therapy ANPD001 in Parkinson’s diseaseLONDON–(BUSINESS WIRE)–#automation—Mytos, an innovative leader in automated cell manufacturing, has entered into a manufacturing collaboration with Aspen Neuroscience, Inc. to automate the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs) for ANPD001, Aspen’s investigational cell therapy program for Parkinson’s disease (PD).The DANPCs, designed to replace lost dopamine-producing neurons in the brain, are differentiated from induced pluripotent stem cells (iPSCs), which are derived from the patient’s own skin cells. This approach holds the promise of restoring lost function without the need for immunosuppressive drugs.As part of the partnership agreement, Aspen will integrate Mytos’ iDEM automated cell culture technology into its new manufacturing facility in Torrey Pines, Calif. The iDEM automated cell culture technology combines fluidics, advanced imaging, and mechanical movement and control to enable fully hands-off production of specific human cell types. This agreement represents the potential for substantial payments to Mytos over the coming years.Mytos’ automation has the potential to drive substantial improvements in efficiency and scalability. By closing and automating processes, iDEM empowers operators to manage more batches simultaneously within a smaller cleanroom footprint, minimizing the need for extensive hiring, training, and facility expansions as manufacturing scales out.“We are excited to work with the innovative Mytos team
Generative AI business automation startup Kognitos raised a $20 million Series A led by Khosla Ventures.
Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ Capital and Wing VC.
The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.